LivaNova shares dip despite Q4, 2018 earnings beat

Shares in LivaNova (NSDQ:LIVN) fell today despite the medical device maker posting fourth quarter and full year 2018 earnings that topped expectations on Wall Street. The London-based company posted losses of $210.6 million, or $4.34 per share, on sales of $297 million for the three months ended December 31, seeing losses grow 88.5% while sales grew 6.7% compared with the same period during the previous year. Adjusted to exclude one-time items, earnings per share were $1.12, just ahead of the $1.10 consensus on Wall Street where analysts expected to see sales of $295 million, which the company topped. For the full year, LivaNova posted losses of $189.4 million, or $3.91 per share, on sales of approximately $1.11 billion, seeing losses grow 654.6% while sales grew 9.4% compared with the previous year. After adjusting to exclude one-time items, earnings per share were $3.55, just in line with the consensus on Wall Street where analysts expected to see sales of $1.11 billion, which the company met. “We had a strong fourth quarter, which allowed us to achieve all of our targets for 2018. Neuromodulation benefited from commercial expansion in our rest of world region and continued strong performance of our SenTiva vagus nerve stimulation therapy system, in the U.S. and Europe. Cardiovascular maintained solid growth, driven by double-digit sales growth for our S5 heart-lung machine and our oxygenator businesses. We are pleased with the progress of our recently acquired adva...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Featured MassDevice Earnings Roundup Wall Street Beat LivaNova Source Type: news